MedTrace Logo

RTX001 Autologous Engineered Macrophages for Liver Cirrhosis

NCT06823713 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-28

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.

Conditions

  • End-stage Liver Disease (ESLD)
  • Cirrhosis, Liver
  • Cirrhosis, Decompensated
  • Liver Diseases
  • Fibrosis and Cirrhosis of Liver
  • Decompensated Liver Cirrhosis
  • Decompensated Cirrhosis
  • Steatotic Liver Disease

Interventions

DRUG

RTX001

RTX001 is an autologous engineered regenerative macrophage cell therapy

Sponsors & Collaborators

  • Resolution Therapeutics Limited

    lead NETWORK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2028-08-29
Completion
2028-11-29

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06823713 on ClinicalTrials.gov